HIF1A and colonic neoplasm: In the shPrPc HCT116 xenograft models, TRAIL treatment led to a significant decrease in tumor volume associated with lower PrPc expression, even though the expression of HIF-1α increased in the xenograft tumor mass, indicating that silencing of PrPc protein is an efficient strategy to inhibit colon cancer development (Figure 7).